EGFR and colorectal carcinoma: Although treatment selection may be a major reason for the longer survival observed in the present study as compared with previous studies involving metastatic CRC patients, univariate analysis revealed no significant differences in survival between patients with and without anti-EGFR therapy (38.8 months vs 32.6 months, P=0.277) (Table 3).